Special attention is directed to the potential application of human induced pluripotent stem (iPS) cell-derived cardiomyocytes for cardiac safety pharmacology and toxicology with fewer legal and ethical issues. Supply of commercially available products enables many researchers to test the utility in their own systems. Although variations of electrophysiological properties have been reported among pluripotent cell lines by classifying cardiac subtypes into nodal, atrial and ventricular cells, most cells are spontaneously contracting, which makes difficult to be implicated in adult human hearts. Thus, we sought objective description on action potential (AP) parameters recorded from perforated patch-clamped iCell cardiomyocytes (iCell-CMs, AJ/CDI) by systematically comparing with those from human ES-derived cardiomyocytes (hES-CMs, Cellartis). Mean þ/-SE values of APD 50 in iCell-CMs (382 þ/-38 ms, n=36) were significantly longer than those in hES-CMs (278 þ/-28 ms n=64), while APD 90 in iCell-CMs (1210 þ/-346 ms, n=36) tended to be longer than those in hES-CMs (776 þ/-136 ms n=64). As for APD 90 , despite of the large sample size, there was no statistical significance between iPS-CM and hES-CMs. Detailed analysis of the variation by Gaussian fitting revealed that marked differences in shapes of probability distribution between iPS-CMs and hES-CMs. Although further studies are necessary to know if the variation of AP parameters affect drug responses, our data provide important information for cardiac safety assessments.
Intracellular calcium overload has been linked to arrhythmias in conditions such as ischemia reperfusion, heart failure, catecholaminergic polymorphic ventricular tachycardia and digitalis intoxication. While this link has been extensively studied at the cellular level using animal models, there is a paucity of information on the causes and consequences of Ca 2þ overload in healthy human myocytes. With the advent of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM), human myocytes are becoming more readily available. However, it remains unclear if these myocytes faithfully recapitulate all aspects of adult cardiomyocyte physiology. In order to determine if iPSC-CM will be a useful platform to study the causes and consequences of Ca 2þ overload, we developed methodology to examine Ca 2þ overload in beating clusters of iPSC-CM and in isolated myocytes. Spontaneous and field stimulated action potentials were measured with high resistance microelectrodes in spontaneously beating clusters of iPSC-CM while measuring cluster contraction with simultaneous video edge detection. Free intracellular Ca 2þ was measured with fluo-4 and confocal microscopy in beating clusters and in isolated iPSC-CM. Ca 2þ overload was induced in both preparations by treatment with ouabain (2.5-5 uM or with isoproterenol (1 uM) plus 5.4 mM extracellular Ca 2þ . Both maneuvers produced a rise in diastolic Ca 2þ as well as the appearance of oscillatory action potentials, putative delayed afterdepolarizations and triggered activityies in beating clusters. These results indicate that iPS-derived cardiomyocytes provide a useful platform to study the mechanisms of Ca 2þ overload-induced arrhythmias as well as possible treatments. However, given the spontaneous nature of iPS-derived cardiomyocytes, these cells may more readily recapitulate the effects of Ca 2þ overload on sinoatrial or latent pacemaker cells.
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Characterization of a Transient Outward K D Current in Hips-Derived Cardiomyocytes Jonathan M. Cordeiro, Vladislav V. Nesterenko, Robert J. Goodrow, Serge Sicouri, Jacqueline A. Treat, Michael X. Doss, Charles Antzelevitch, José M. Di Diego. Masonic Medical Research Laboratory, Utica, NY, USA. Background: Human induced pluripotent stem cell (hiPS)-cardiomyocytes can be used to create in vitro models of genetic disease such as Brugada Syndrome (BrS). Central to the development of BrS is the Ca 2þ -independent transient outward K þ current (I to ). In this study, we characterized I to in single hiPS -cardiomyocytes and determined its functional role in beating clusters.
Methods: Embryoid bodies (EBs) were made from a hiPS cell line reprogrammed with Oct4, Nanog, Lin28 and Sox2. Whole cell patch clamp was used to record I to in single hiPS cardiomyocytes. Action potential (AP) recordings from spontaneously beating clusters (BCs) were made using sharp microelectrodes. All recordings were done at 36 C. Results: BCs exhibited spontaneous APs with an average rate of 54.9530.1 bpm and maximum diastolic potential (MDP) of À65.659.3 mV (n=122). A small phase 1 repolarization which could be blocked by 4-AP (1 mM) was observed in 6/149 hiPS BCs suggesting the presence of I to . Interestingly, in single dissociated hiPS cardiomyocytes, patch clamp analysis revealed a robust I to (13.451.79 pA/pF at þ40 mV, n=14) in the majority of cells studied. Recovery of I to (at À80 mV) showed a fast and slow phase as follows: i) 1=271593 ms and 2= 26975103 (n=8 cells). These observations demonstrate that I to is present but the slow recovery suggests minimal contribution during the course of an action potential. Mathematical modeling of APs from hiPSC-CMs confirmed these observations. Conclusion: There is a disconnect between the presence of I to in cells and the absence of phase 1 repolarization in BCs. In BCs the depolarized MDP and fast spontaneous AP rate suggests negligible contribution of I to to phase 1 repolarization. Our results point to an important deficiency of hiPSC-CMs in recapitulating the phenotype of adult native myocytes.
1527-Pos Board B419 Analysis of Zolpidem-Induced Long Qt Syndrome in Recombinant hERG Channels and Stem Cell Derived Human Cardiomyocytes
Julian Jehle 1 , Xiaoping Wan 2 , Isabelle Deschenes 2 , Dierk Thomas 1 , Eckhard Ficker 2 . 1 Medical University Hospital, Heidelberg, Germany, 2 Case Western Reserve University, Cleveland, OH, USA. Zolpidem, a short-acting hypnotic drug prescribed to treat insomnia, has been clinically associated with acquired long QT syndrome (acLQTS) and torsade de pointes tachyarrhythmias (TdP). Because acLQTS is most often precipitated by a reduction of hERG/I Kr currents, we have studiedacute hERG block by zolpidem in HEK cells using patch clamp recordings. We found that zolpidem reduced hERG currents with an IC 50 value of 65.5 5 4.5 mM (n=3-6).
In marked contrast to many other hERG blockers, hERG surface expression was not impaired on long-term drug exposure. To determine whether zolpidem effects in an expression system are relevant to cardiac electrophysiology, we studied human stem cell-derived cardiomyocytes (iCells, CDI, Madison, WI). In human cardiomyocytes, zolpidem prolonged APD 90 significantly from 321.2 5 45.5 ms (n = 9) under control conditions to 375.8 5 55.5 ms (n=9) and 414.1 5 54.8 ms (n=9) in the presence of 10 mM and 30 mM zolpidem, respectively. Because zolpidem produced TdP in combination with the antiarrhythmic drug amiodarone, we investigated whether both drug effects were additive. When amiodarone was applied separately, APD 90 prolonged from 287.5 5 30.8 ms (n=8) under control conditions to 349.6 5 50.4 ms, and 403.0 5 59.1 ms (n=8) with 100 nM and 1 mM amiodarone (n=7), respectively. When amiodarone (100nM) and zolpidem were co-administered, APD 90 was further prolonged from 341.0 5 45.3 ms (n=8) during amiodarone treatment to 381.3 5 38.1 ms with 10 mM (n = 8) and 450.3 5 50.2 ms with 30 mM zolpidem (n = 8). Taken together, our results indicate that acute zolpidem administration blocks hERG channels and induces cardiac action potential changes that are consistent with clinically observed QT prolongation, particularly in patients treated with multiple medications. We have detected structural dynamics of the sarcoplasmic reticulum Ca-ATPase (SERCA) using time-resolved fluorescence spectroscopy. The Ca-ATPase from fast-twitch skeletal muscle (SERCA1a isoform) was labeled with cyan fluorescent protein (CFP) at the N-terminus in the actuator domain (A) and fluorescein isothiocyanate (FITC) at Lys-515 in the nucleotidebinding domain (N). Time-resolved FRET was detected between CFP (donor in A domain) and FITC (acceptor in N domain) for SERCA in ligandstabilized states, including calcium-free (E2), calcium-bound (E1), and actively-cycling phosphoenzyme (EP). Lifetime fitting and molecular modeling were used to interpret fluorescence decays, thereby identifying a dynamic distribution of structural states within the cytoplasmic headpiece of SERCA 298a (i.e., A-N interdomain distance). FRET results were compared to distance predictions from x-ray crystallography. We propose a structural mechanism for ligand activation of SERCA. Acknowledgments: Spectroscopy was performed in the Biophysical Spectroscopy Center at the University of Minnesota, with assistance from Fluorescence Innovations, Inc. (Gregory Gillispie, President). This work was funded by NIH grants to DDT (R01 GM27906, P30 AR0507220, T32 AR007612).
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Screening for SERCA Activators using a High-throughput Time-Resolved FRET Assay Ji Li 1 , Holly Langer 1 , Kurt C. Peterson 2 , Joseph M. Muretta 1 , Gregory D. Gillispie 1 , Razvan L. Cornea 1 , David D. Thomas 1 . 1 University of Minnesota, Minneapolis, MN, USA, 2 Fluorescence Innovations, Inc., Minneapolis, MN, USA. We used a prototype time-resolved fluorescence lifetime microplate reader to carry out a high-throughput screen designed to identify compounds that interact with the sarcoplasmic reticulum calcium ATPase (SERCA). SERCA is essential for the Ca homeostasis in many cell types. Insufficient SERCA activity leads to cardiovascular disease, muscular dystrophy, skin disease, and diabetes. Our goal is to discover activators of SERCA that can be developed into drugs to treat diseases in which Ca transport is deficient. The fluorescence lifetime plate reader was made possible by our recent development of fast time-resolved fluorescence by direct waveform recording, which achieves 105 higher throughput than the conventional single-photon counting technology. using this plate reader, we detected fluorescence resonance energy transfer (FRET) between IAEDANS-labeled SERCA and nucleotide analog TNPADP in native sarcoplasmic reticulum membranes. This assay was designed to detect compounds that interact with SERCA and modify either the enzyme's structure or the binding affinity of TNP-ADP. Initial hit compounds were further analyzed in functional assays. Upon screening a small (1300 compound) library, we determined that the time-resolved microplate reader has at least 10x higher precision than a conventional intensity-based microplate reader, raising the quality index (z') of our assay from marginal, in the intensity reader, to excellent. A 384-well plate is read with high precision in 2 min, which allows screening of thousands of compounds/day. An important advantage of the time-resolved fluorescence measurement is that it provides detailed structural information, thus enabling discovery of multiple classes of compounds during the primary screen.
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In-Cell FRET as a Tool to Develop SERCA Activators for Drug or Gene Therapy Simon J. Gruber 1 , Kurt C. Peterson 1 , Bengt Svensson 1 , Seth L. Robia 2 , David D. Thomas 1 . 1 University of Minnesota, Minneapolis, MN, USA, 2 Loyola University, Chicago, IL, USA. We are using in-cell FRET methods (Photobleaching, FLIM, time-resolved FRET in a plate reader) to study the relationships among structure, dynamics, and function of the sarcoplasmic reticulum Ca-ATPase (SERCA) and its cardiac regulator phospholamban (PLB), with the goal of designing activators of SERCA for treatment of heart failure (HF) and muscular dystrophy (MD). Ca 2þ drives muscle contraction, and relaxation is accomplished by the sequestration of Ca 2þ by the sarcoplasmic reticulum Ca-ATPase (SERCA), which is inhibited by phospholamban at submicromolar [Ca 2þ ] in cardiac muscle. SERCA activity is frequently reduced in HF, and many current therapeutic strategies aim to increase cardiac Ca 2þ cycling activity. We are designing LOF-PLB mutants (PLB M ) that can compete with WT-PLB (PLB W ) and thus relieve SERCA inhibition. Our ideal mutant is partial loss-of-function, binds tightly to SERCA2a, and remains phosphorylatable via b-adrenergic pathways. The effects of PLB M on Ca-ATPase activity and FRET are measured to determine the mutant's ability to compete with PLB W , both physically and functionally. Optimal LOF mutants are being tested in a rat model of heart failure. In addition to this SERCA-PLB FRET competition assay, we are using SERCA2a labelled with two different fluorescent probes (GFP and RFP) to screen for small molecule activators of SERCA in living cells. Timeresolved FRET measurements of RFP-GFP-SERCA2a in 96-or 384-well plates have shown the extraordinary precision and sensitivity necessary to probe SERCA's structure-function relationship. New drug screening efforts are active and small molecules from previous screens are being developed as promising drugs for HF therapy (collaboration with Celladon, Inc.). Many of these drugs are direct SERCA activators and are being investigated for their ability to rescue the muscular dystrophy phenotype in dystrophic mice. We have used site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy to investigate the effects of Ser16 phosphorylation on phospholamban's interaction with the sarcoplasmic reticulum Ca-ATPase (SERCA). Muscle contraction is signaled by the release of Ca from the sarcoplasmic reticulum (SR), while SERCA mediates muscle relaxation by actively pumping Ca back into the SR lumen. Cardiac SERCA is regulated by phospholamban (PLB), a single-pass transmembrane protein that inhibits the Ca pump unless phosphorylated at Ser16. We have shown that Ser16 phosphorylation does not dissociate PLB from SERCA to relieve inhibition, but instead induces a structural change in PLB's transmembrane (TM) helix that restores SERCA Ca sensitivity. To characterize this change, we have attached spin labels along the TM helix and performed EPR accessibility measurements to determine the effects of Ser16 phosphorylation on TM helix topology within the regulatory complex. Our results show that upon phosphorylation, the TM helix undergoes a vertical shift that could break inhibitory interactions between SERCA and PLB. Complementary ongoing studies employ these spin-labeled PLB constructs to determine changes in (a) the orientation of PLB and (b) distances to probes on SERCA, with the goal of obtaining a detailed structural model for the regulatory transitions within the SERCA-PLB complex. We have used electron paramagnetic resonance (EPR) to probe the structural dynamics of the integral membrane protein phospholamban (PLB), as a function of phosphorylation and addition of its regulatory target, the sarcoplasmic reticulum calcium ATPase (SERCA). We found previously that PLB remains bound to SERCA after phosphorylation, suggesting that a structural transition within the SERCA-PLB complex is responsible for relief of inhibition. Our current goal is to elucidate this mechanism through orientation and accessibility EPR, in order to support rational design of therapies to improve calcium transport in muscle cells. We used the monomeric mutant AFA-PLB, with the rigid electron spin label TOAC incorporated within the transmembrane domain, and reconstituted the protein in lipid bicelles and vesicles. EPR showed that the accessibilities of PLB spin labels to paramagnetic relaxation agents changed upon phosphorylation, indicating vertical (parallel to the membrane normal) movement of PLB. EPR on aligned bicelles showed that PLB changes its tilt relative to the membrane upon phosphorylation. Results will also be reported on structural changes in the presence of SERCA. This work was funded by grants from NIH (R01 GM27906 and T32 AR007612).
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Probing Cardiac Membrane Proteins with Fluorescence Resonance Energy Transfer Xiaoqiong Dong, Ji Li, Christine B. Karim, David D. Thomas. University of Minnesota, Minneapolis, MN, USA. We have used time-resolved fluorescence resonance energy transfer (TR-FRET) to study the structural basis of regulation of sarcoplasmic reticulum Ca 2þ ATPase (SERCA) by a single-pass transmembrane protein, phospholamban (PLB). The most prominent feature of heart failure is calcium mishandling, which is largely due to impaired activity of sarcoplasmic reticulum calcium ATPase (SERCA), which actively transports Ca 2þ from cytosol into the SR to relax the muscle. Unphosphorylated phospholamban inhibits SERCA by decreasing its apparent Ca 2þ affinity. This inhibition can be relieved by either micromolar Ca 2þ or by phosphorylation of PLB. The structural basis for relief of inhibition remains controversial. Cross-linking studies support the canonical dissociation model. However, recent EPR, NMR and FRET studies support the subunit model, in which subtle structural rearrangements are required to
